What the WADA Prohibited List Is, and How It Changes Each Year

The World Anti-Doping Agency (WADA) Prohibited List is the single, globally binding document that names which substances and methods are banned in sport, and when. It is one of the International Standards under the World Anti-Doping Code, which means every signatory sport and every national anti-doping organization works from the same List. WADA revises it once a year through expert review and stakeholder consultation, publishes the new version by 1 October, and brings it into force the following 1 January. The 2026 List, agreed by WADA's Executive Committee in September 2025, took effect on 1 January 2026, following exactly that cycle.

This article explains how the List is organized and how it changes, at the level of governance and structure. It is educational and not medical advice.

How the List is organized

The List sorts everything it covers by when a prohibition applies, not by chemistry alone. Three tiers do most of the work.

The first tier is substances and methods prohibited at all times, in and out of competition. This covers the categories most people associate with doping: anabolic agents (S1), peptide hormones and growth factors (S2), beta-2 agonists (S3), hormone and metabolic modulators (S4), diuretics and masking agents (S5), and a catch-all for non-approved substances (S0). The prohibited methods sit here too: manipulation of blood and blood components (M1), chemical and physical manipulation (M2), and gene and cell doping (M3).

The second tier is substances prohibited in-competition only. These are things WADA judges to carry a doping risk during competition but not necessarily around the clock: stimulants (S6), narcotics (S7), cannabinoids (S8), and glucocorticoids (S9).

The third tier is substances prohibited in particular sports, currently beta-blockers (P1), which matter in precision disciplines like archery and shooting.

Within those tiers, WADA also flags whether a substance is specified or non-specified. That distinction does not change whether something is banned; it changes how a resulting case is handled, because specified substances are ones more likely to be consumed for legitimate, non-doping reasons and so allow more flexibility in sanctioning. The 2026 List keeps this architecture intact and, as WADA describes in its published summary of modifications, mostly refines the examples inside each category rather than moving the boundaries between tiers.

Why a substance or method gets listed

WADA does not add things arbitrarily. A substance or method is considered for inclusion when it meets any two of three criteria: it has the potential to enhance sport performance; it poses an actual or potential health risk to the athlete; or it violates what the Code calls the spirit of sport. A substance that masks the use of another prohibited substance can also be included on that basis alone. The "two of three" rule is worth sitting with, because it explains why the List is not simply a catalogue of performance enhancers. Health risk and the spirit-of-sport principle carry independent weight, which is how categories that do little for performance can still be prohibited.

Between the List and open permission sits a third status: the Monitoring Program. Substances there are not prohibited, and an athlete using them commits no violation, but WADA tracks their use to detect emerging patterns of misuse. Items sometimes move from monitoring onto the List once evidence accumulates, which is one way the List grows in a deliberate, evidence-led way rather than by reaction.

How it changes each year

The annual revision is a structured, roughly year-long process, not an internal edit. It begins early in the year, when WADA's List Expert Advisory Group reviews the latest scientific and medical literature, doping trends, and intelligence shared by law enforcement and the pharmaceutical sector. A draft List then circulates to stakeholders, including anti-doping organizations, athletes, and governments, and their submissions feed a revised draft that the Agency's Health, Medical and Research Committee reviews before the Executive Committee approves it. Publishing by 1 October, three months ahead of the 1 January effective date, is a deliberate feature: it gives athletes and their support staff a fixed window to check medications and adjust, rather than facing a rule that changes without warning.

The 2026 cycle illustrates the kind of change this produces. Most modifications were clarifications: added examples in the anabolic agents (S1), peptide hormones (S2), and hormone and metabolic modulators (S4) sections to help readers correctly identify what is covered, including an explicit note that esters of prohibited steroids are themselves prohibited. Genuinely new entries were narrow and specific. WADA added the non-diagnostic use of carbon monoxide as a new method sub-section (M1.4), while preserving its legitimate diagnostic use, and extended the gene-and-cell-doping provisions to cover cell components such as mitochondria and other organelles. These are refinements at the edges of existing categories, which is the typical texture of a year-over-year update.

Reading the List correctly

Two habits protect against misreading it. First, the List states categories and representative examples, not an exhaustive inventory; a substance can be prohibited because it belongs to a named class even if its specific name never appears, which is precisely what the "including but not limited to" language and the S0 non-approved category are designed to capture. Second, an item's status can depend entirely on timing and sport, so "banned" is rarely a simple yes or no without asking when and in which discipline. The List is best understood as a living governance instrument with a fixed annual rhythm: reviewed continuously, decided by defined criteria, published on a predictable schedule, and applied uniformly across world sport.